| Overview |
| bs-12207R-Cy5.5 |
| UTF1 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Cow |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UTF1 |
| 101-170/341 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 8433 |
| Nucleus |
| hUTF 1; hUTF1; Undferentiated embryonic cell transcription factor 1; UTF 1; UTF1; UTF1_HUMAN. |
| UTF1 is a 341 amino acid protein that localizes to the nucleus and is subject to post-translational phosphorylation. Associating with the TFIID complex via an interaction with the TATA box binding protein (TFIID), UTF1 binds to the N-terminal region of ATF-2 and, via this binding, acts as a transcriptional coactivator of ATF-2, thereby enhancing transcriptional activity. Human UTF1 shares 64% homology with its mouse counterpart, suggesting a similar role between species. The gene encoding UTF1 maps to human chromosome 10, which houses over 1,200 genes and comprises nearly 4.5% of the human genome. Defects in some of the genes that map to chromosome 10 are associated with Charcot-Marie Tooth disease, Jackson-Weiss syndrome, Usher syndrome, nonsyndromatic deafness, Wolman?s syndrome, Cowden syndrome, multiple endocrine neoplasia type 2 and porphyria. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz